Cascadian Therapeutics
Cascadian Therapeutics was a Seattle-based, clinical-stage bio-pharmaceutical company that researched and developed therapeutic products for cancer treatment. Founded in 1985, it operated with 51-100 employees and pursued oncology assets via acquisition and equity financings prior to its delisting.
- Company typePrivate
- Founded1985
- HeadquartersSeattle, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cascadian Therapeutics does
Cascadian Therapeutics was a bio-pharmaceutical company based in Seattle, Washington, that researched, developed, and commercialized therapeutic products for the treatment of cancer. Founded in 1985, the company operated at a small scale of 51-100 employees and was publicly traded on NASDAQ under the ticker CASC before being delisted. The firm pursued a pipeline-driven oncology strategy, executing two disclosed acquisitions: ProlX Pharmaceuticals Corp. in October 2006 (undisclosed consideration) and Alpine Biosciences in August 2014 for approximately $27 million, indicating a roll-up approach to assembling therapeutic assets.
Capital formation activity between 2010 and 2016 totaled approximately $64.9 million across four disclosed funding rounds, with participation from institutional investors including Ayer Capital Management, Cowen Group, Dafna Capital Management, Heights Capital Management, Iroquois Capital, Biotechnology Value Fund, and New Enterprise Associates. Leadership included Robert L. Kirkman as President & CEO and Scott R. Peterson as Chief Scientific Officer. No commercial products, revenue figures, customer relationships, or distribution channels are disclosed in the available data, and the domain CascadianRx.com is currently listed for sale by HugeDomains at $2,995 rather than functioning as an active corporate site, signaling limited current operational presence.
Cascadian Therapeutics firmographics
Firmographics- Name
- Cascadian Therapeutics
- Website
- https://cascadianrx.com
- Company type
- Private
- Founded year
- 1985
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cascadian Therapeutics was a Seattle-based, clinical-stage bio-pharmaceutical company that researched and developed therapeutic products for cancer treatment. Founded in 1985, it operated with 51-100 employees and pursued oncology assets via acquisition and equity financings prior to its delisting.
- Ownership category
- akta.pro rank
Cascadian Therapeutics industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industry
- Medical Oncology (HLAKAFAB)
Keywords
Where Cascadian Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Markets served
Cascadian Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain
Cascadian Therapeutics product offering
Product offeringCore offering
Cascadian Therapeutics is a bio-pharmaceutical company that researches, develops, and sells therapeutic products for the treatment of cancer. The company was founded in 1985, headquartered in Seattle, USA, and historically operated with 51-100 employees focused on oncology drug development. Its prior NASDAQ ticker was CASC, and the company pursued acquisitions of complementary biotech firms such as Alpine Biosciences and ProlX Pharmaceuticals to expand its oncology pipeline.
Differentiator
Problem solved
Functional benefit
Products and services
- Oncology therapeutic products
Companies that use Cascadian Therapeutics
Customer profileIdeal customer profiles1 record
Cascadian Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cascadian Therapeutics partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights2 records
Cascadian Therapeutics competitors and assessment
Company assessmentMarket position
Competitive moat2 records
Key highlights6 records
Customer concentration
Cascadian Therapeutics social profiles
Digital presenceCascadian Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cascadian Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Cascadian Therapeutics funding detail
Funding detailFunding overview
Funding rounds4 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cascadian Therapeutics M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cascadian Therapeutics
What does Cascadian Therapeutics do?
Cascadian Therapeutics is a bio-pharmaceutical company that researches, develops, and sells therapeutic products for the treatment of cancer. The company was founded in 1985, headquartered in Seattle, USA, and historically operated with 51-100 employees focused on oncology drug development. Its prior NASDAQ ticker was CASC, and the company pursued acquisitions of complementary biotech firms such as Alpine Biosciences and ProlX Pharmaceuticals to expand its oncology pipeline.
When was Cascadian Therapeutics founded?
Cascadian Therapeutics was founded in 1985. It employs 51 to 100 people.
Where is Cascadian Therapeutics based?
Cascadian Therapeutics is headquartered in Seattle, United States, in the North America region.
Does Cascadian Therapeutics have an API?
No public API is recorded for Cascadian Therapeutics.
What industry is Cascadian Therapeutics in?
Cascadian Therapeutics's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 325412 and its SIC code is 2834.